![Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial - The Lancet Oncology Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/4eb32990-3fe7-4b04-bbe1-fa61bdbc7c2b/gr1.jpg)
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial - The Lancet Oncology
![Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity | PNAS Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity | PNAS](https://www.pnas.org/cms/10.1073/pnas.0609757104/asset/204468c0-d1ff-46c2-9f4f-0222958e52d8/assets/graphic/zpq0080754460006.jpeg)
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity | PNAS
![Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial - The Lancet Oncology Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/83343cbe-918f-402f-9526-a626ef55f751/gr1_lrg.gif)